142results about How to "Potent effect" patented technology

This invention provides methods of obtaining vaccines by use of non-stochastic methods of directed evolution (DirectEvolution(TM)). These methods include non-stochastic polynucleotide site-satuaration mutagenesis (Gene Site Saturation Mutagenesis(TM)) and non-stochastic polynucleotide reassembly (GeneReassembly(TM)). Through use of the claimed methods, vectors can be obtained which exhibit increased efficacy for use as genetic vaccines. Vectors obtained by using the methods can have, for example, enhanced antigen expression, increased uptake into a cell, increased stability in a cell, ability to tailor an immune response, and the like.

The present invention relates to a panel of targeted therapy markers that can be used in assessing a particular subject's sensitivity to various therapeutic agents and cancer treatments as a means of prognosticating whether a treatment or use of a particular therapeutic agent will result in a clinically positive outcome. Cellular receptors, ligands to those receptors and molecules involved in the programmed cell death pathway are examples of targeted therapy markers that might be used in the present invention.

This invention provides methods of obtaining novel polynucleotides and encoded polypeptides by use of non-stochastic methods of directed evolution (DirectEvolution(TM)). These methods include non-stochastic polynucleotide site-saturation mutagenesis (Gene Site Saturation Mutagenesis(TM)) and non-stochastic polynucleotide reassembly (GeneReassembly(TM)). Through use of the claimed methods, genetic vaccines, enzymes, and other desirable molecules can be evolved towards desirable properties. For example, vaccine vectors can be obtained that exhibit increased efficacy for use as genetic vaccines. Vectors obtained by using the methods can have, for example, enhanced antigen expression, increased uptake into a cell, increased stability in a cell, ability to tailor an immune response, and the like. This invention provides methods of obtaining novel enzymes that have optimized physical &/or biological properties. Furthermore, this invention provides methods of obtaining a variety of novel biologically active molecules, in the fields of antibiotics, pharmacotherapeutics, and transgenic traits.

Cardiac stroke volume (SV) of a subject is estimated as a function of a value derived from a measured arterial pressure waveform. The value may be the standard deviation, or a function of the difference between maximum and minimum pressure values, or a function of either the maximum value of the first time derivative or the absolute value of the minimum of the first time derivative of the pressure waveform, or both, or a function of the magnitude of one or more spectral components of the pressure waveform at a frequency corresponding to the heart rate. Cardiac output is then estimated as the product of the subject's heart rate and SV, scaled by a calibration constant. Arterial pressure may be measured invasively or non-invasively.

Method and apparatus for providing a fault tolerant display unit for an electronic device such as a glucose meter, including display unit, and a controller unit operatively coupled to the display unit, the controller unit configured to control the display unit to display an information, where when a failure mode of the display unit occurs, the display unit is configured to display a modified information, where the modified information is different from the information for display under the control of the controller unit, is provided.

Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric form of Nicotine, nicotinic acid analogs thereof, their combination with or without other pro-angiogenesis factors, vasodilator, or other therapeutic modalities to promote angiogenesis in the subject. This is composition and combination thereof is applicable to improving wound healing, erectile dysfunction, improving collateral or blood supply in patients with myocardial infarction, stroke, peripheral artery diseases, and other vascular disorders as disclosed.

A new type of fine metal mask (FMM) used in OLED production and the method of manufacturing it, wherein the FMM includes a frame made of a metal substrate with a plurality of through holes, a layer of fine mask electroformed on the surface of the frame so that said fine mask and said frame are seamlessly integrated, said fine mask is divided into a pattern area and a border area, and the pattern area corresponds to the through holes on the frame, and the method of manufacturing such an FMM comprising the steps of: A. providing a metal substrate by cutting an invar alloy or stainless steel plate to a desired size; B. providing an fine mask by adding a photoresist layer on the metal substrate, exposing a desired pattern onto said photoresist layer, and electroforming a metal base layer and a metal layer with a low thermal expansion coefficient; and C. etching the metal substrate by etching out a pattern area of the metal substrate that corresponds to the pattern area of said fine mask using a chemical etching method to form a plurality of through holes, and creating an outer border area and internal separation area for support of said fine mask.

An electronic drive system applies a drive signal to an electrostatically actuated device such that a resulting electric field has a constant force. In various exemplary embodiments, the electronic drive system applies a drive signal to an electrostatically actuated fluid ejector that has a piston and a faceplate including a nozzle hole. A dielectric fluid to be ejected is supplied between the piston and the faceplate. The drive signal is applied to one of the piston and the faceplate. The drive signal generates an electric field across the fluid between the piston and the faceplate. The electric field causes the piston to be electrostatically attracted towards the faceplate so that a jet or drop of fluid is ejected through the nozzle hole of the faceplate. According to exemplary embodiments, the drive signal is from a constant current source or is reduced over the course of its lifetime. Further, according to various exemplary embodiments, the drive signal is of a suitable high frequency to reduce the potential of electrochemical reactions or electrical breakdown, or both. The drive signal may also be a bi-polar drive signal to reduce the possibility of electrochemical reactions.

A method of processing an Orthogonal Frequency-Division Multiplex (OFDM) signal having a plurality of data carriers and a plurality of unused carriers is disclosed. The method comprises transforming an original frequency-domain OFDM signal into a time domain signal and simulating the effect of a non-linear amplifier on the time-domain signal to provide a potentially distorted time domain signal. The potentially distorted time domain signal is transformed into a potentially distorted frequency domain signal and at least some of any values of the data carriers in the potentially distorted frequency domain signal are restored with corresponding values from the original frequency domain signal. At least some of the unused carriers in the at least partially restored frequency domain signal are scaled with a scaling factor. The scaled frequency domain signal is transformed into a temporary time domain signal and the temporary time domain signal is analysed for the presence of a peak or near zero amplitude value that would lead to distortion by said amplifier. If the signal includes such a peak or near zero value, the scaling, transforming and analysing are repeated with an increased scaling factor.

Described are methods of treating a cancer comprising administering to a subject in need thereof an effective amount of a dopamine receptor (DR) antagonist. The DR antagonist may be a phenothiazine derivative, such as thioridazine or chlorpromazine. Optionally, the cancer is acute myeloid leukemia. Also described are methods for identifying subjects with cancer, methods for providing a prognosis for a subjects with cancer and methods for identifying subjects likely to be responsive to therapy with DR receptor antagonists. Methods for identifying cancer stem cells and chemotherapeutic compounds that are DR receptor antagonists as also provided. Also described are methods for the identification and validation of agents that target cancer stem cells.

A Method for the treatment of skin fibrosis with a peptide that inhibits TGF-β, and suitable compositions for its administration. The method includes in particular, the use of peptide P144, a compound that is a known inhibitor of TGF-β, for the treatment of skin fibrosis by topical application. The method is shown effective in an animal model of bleomycin-induced skin sclerosis, to a reduction both of the skin fibrosis and of the content of soluble collagen, without any signs of systemic toxicity being detected. This shows that P144 is effective for topical application in mammals for treating fibrotic skin diseases and pathological scarring of the skin. For the administration of this peptide, stable compositions are also supplied, with pleasant appearance without being greasy, with good spreading characteristics and with a viscosity that permits it to be processed easily in industrial plant, and which are suitable for administering the peptide to humans.

A method for administering a therapeutic agent which inhibits the mechanistic pathways necessary to maintain the progression of lethal shock. The therapeutic agent is administered in the form of a drug, antisense or protein depending on the gene expression.

A pharmaceutical anesthetic composition for topical administration for dental, emergency and general medical use is described. The composition is a eutectic composition of anesthetic agents, sugar alcohol, and menthol for the purpose of numbing oral or dermal tissue. Methods of making and of using the composition are described.

The present invention relates to a method of treating and/or preventing cancer comprising administering a combination of an effective amount of a DNA hypomethylating agent and an effective amount of at least one immunomodulatory agent and/or optionally an effective amount of at least one targeted therapy agent.

The invention provides a compound comprising a photosensitising agent coupled to a carrier molecule with a minimum coupling ratio of 3:1 wherein the carrier molecule has a binding specificity for a target cell. There is also provided a process of conjugation comprising the use of a first and second aprotic solvent and uses of the conjugated compounds.

There is provided a drug therapy for prevention of glaucoma or prevention or treatment of ocular hypertension, with a potent ocular hypotensive effect and prolonged duration thereof. Disclosed is a combination of (S)-(−)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or a salt thereof, or a solvate thereof, and a prostaglandin for prevention or treatment of glaucoma.

A composition for chemical-mechanical polishing, comprising an aqueous solution and an abrasive that comprises polymer particles, is described. The polymer particles carry an electrical charge, such that nearby particles repel one another. Accordingly, aggregation of polymer particles may be reduced, minimized or eliminated. The composition may additionally comprise an oxidizing agent. A method of using the composition to polish a substrate surface, such as a substrate surface having a metal surface feature or layer, is also described. A substrate so polished may exhibit good surface characteristics, such as a relatively smooth surface or a reduced number of, or a lack of, microscratches on the surface of the substrate.

Embodiments of the present invention provide for methods and compositions comprising an Oncorasin, such as 1-[(4-chlorophenyl)methyl]-1H-indole-3-carboxaldehyde (oncrasin-1) and/or its analogs or derivatives.

A procedure and machine promotes healing by causing muscle fasciculation and contraction relaxation cycles that effectively pump blood through the microcirculation, draining the venous beds and raising the tissue oxygen levels. A high phase charged system is electronically pulsed and adjusted to induce deep-layered muscle contractions, causing greatly increased flow rates of both blood and lymphatics, patency of vessels permitting, and forcing blood into the microcirculation of the treated tissue. The machine electrical waveform stimulates angiogenesis, facilitating new tissue growth and repair in the healing process and raises the metabolic rate in the treated tissues.